Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

NCT04319783 is registered in ClinicalTrials.gov with Trans Tasman Radiation Oncology Group as lead sponsor.

NCT NCT04319783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04319783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Lead sponsor
Trans Tasman Radiation Oncology Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 2, 2021
Completion date
June 30, 2026
Enrollment
65 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate carcinoma, cancer of prostate, castrate resistant prostate cancer, psa